HomeCompareCMOPF vs KO

CMOPF vs KO: Dividend Comparison 2026

CMOPF yields 2.29% · KO yields 2.71%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KO wins by $11.1K in total portfolio value· pulled ahead in Year 4
10 years
CMOPF
CMOPF
● Live price
2.29%
Share price
$105.00
Annual div
$2.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.1K
Annual income
$264.93
Full CMOPF calculator →
KO
The Coca-Cola Company
● Live price
2.71%
Share price
$76.05
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,323.37
Full KO calculator →

Portfolio growth — CMOPF vs KO

📍 KO pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMOPFKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMOPF + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMOPF pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMOPF
Annual income on $10K today (after 15% tax)
$194.28/yr
After 10yr DRIP, annual income (after tax)
$225.19/yr
KO
Annual income on $10K today (after 15% tax)
$230.24/yr
After 10yr DRIP, annual income (after tax)
$3,674.86/yr
At 15% tax rate, KO beats the other by $3,449.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMOPF + KO for your $10,000?

CMOPF: 50%KO: 50%
100% KO50/50100% CMOPF
Portfolio after 10yr
$28.6K
Annual income
$2,294.16/yr
Blended yield
8.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

CMOPF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
9.2
Piotroski
8/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.6% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMOPF buys
0
KO buys
13
PoliticianChamberTickerTypeAmountDate
Markwayne Mullin🏛 Senate$KO▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$KO▲ Buy$15,001 - $50,0002025-12-29
Lloyd Doggett🏢 House$KO▲ Buy$1,001 - $15,0002025-12-15
Sheldon Whitehouse🏛 Senate$KO▲ Buy$1,001 - $15,0002025-11-21
Sheldon Whitehouse🏛 Senate$KO▲ Buy$1,001 - $15,0002025-11-21
Julia Letlow🏢 House$KO▲ Buy$1,001 - $15,0002025-11-03
Lisa McClain🏢 House$KO▲ Buy$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$KO▲ Buy$1,001 - $15,0002025-09-25
Val Hoyle🏢 House$KO▼ Sell$1,001 - $15,0002025-09-23
Ro Khanna🏢 House$KO▼ Sell$1,001 - $15,0002025-09-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMOPFKO
Forward yield2.29%2.71%
Annual dividend / share$2.40$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%24.3%
Portfolio after 10y$23.1K$34.1K
Annual income after 10y$264.93$4,323.37
Total dividends collected$2.5K$15.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: CMOPF vs KO ($10,000, DRIP)

YearCMOPF PortfolioCMOPF Income/yrKO PortfolioKO Income/yrGap
1$10,929$228.56$10,847$336.70+$82.00CMOPF
2$11,927$233.45$11,832$431.92+$95.00CMOPF
3$13,000$238.11$12,992$557.22+$8.00CMOPF
4← crossover$14,153$242.55$14,379$723.66$226.00KO
5$15,390$246.78$16,059$947.18$669.00KO
6$16,718$250.80$18,129$1,251.14$1.4KKO
7$18,143$254.62$20,724$1,670.45$2.6KKO
8$19,671$258.24$24,040$2,258.40$4.4KKO
9$21,310$261.68$28,364$3,098.25$7.1KKO
10$23,067$264.93$34,134$4,323.37$11.1KKO

CMOPF vs KO: Complete Analysis 2026

CMOPFStock

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Full CMOPF Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this CMOPF vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMOPF vs SCHDCMOPF vs JEPICMOPF vs OCMOPF vs MAINCMOPF vs PEPCMOPF vs PGCMOPF vs JNJCMOPF vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.